IMUX, US4525EP2001

Immunic stock: Wall Street Zen downgrades Immunic stock to Sell

Published on 10/22/2026 at 20:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 EPS beat estimates by USD 0.36, reaching a loss of USD 0.80. Immunic stock costs EUR 6.47 on October 22, 2026, down 3.58 percent versus Tradegate.

Rating and earnings facts

Wall Street Zen downgraded Immunic from Hold to Sell on October 10, 2026.
Second-quarter earnings per share beat consensus by USD 0.36 in 2026.
Immunic stock costs EUR 6.47 at Lang & Schwarz on October 22, 2026 at 8:20 p.m. CEST, down 3.58 percent versus the Tradegate close of October 21, 2026.
Yahoo Finance lists November 13, 2026 as the next earnings date.

IMUX, US4525EP2001, Illustration mit AI erstellt.

Wall Street Zen downgraded Immunic from Hold to Sell on October 10, 2026, while MarketBeat reported that the broader analyst consensus remained Buy with an average target of USD 35.43. Immunic, Inc. stock with ISIN US4525EP2001 was trading at EUR 6.47 at Lang & Schwarz on October 22, 2026 at 8:20 p.m. CEST, down 3.58 percent versus the Tradegate close of October 21, 2026 at EUR 6.71.

Quarterly loss beats estimates

The downgrade contrasts with Immunic's latest reported earnings comparison. MarketBeat reported a second-quarter 2026 loss of USD 0.80 per share, which was USD 0.36 better than the consensus estimate of a USD 1.16 loss. The quarter also ended with a net loss of USD 34.10 million, while cash stood at USD 155.10 million on June 30, 2026.

Price remains below yearly high

On the Nasdaq, Immunic was last quoted at USD 7.24 at 2:30 p.m. EDT on October 22, 2026. The primary-exchange quote sits between the 52-week low of USD 5.06 and high of USD 17.43, while the market capitalization was USD 98.80 million and volume reached 342,088 shares.

The euro quotation gives German investors a separate after-hours view. Its 3.58 percent decline versus the Tradegate close is larger than the 2.13 percent gain shown for the German venue on October 21, 2026, so the two figures describe different sessions and venues.

Valuation and next reporting date

Immunic remains a development-stage biotechnology company focused on oral therapies for neurologic and autoimmune diseases. Its lead program, vidofludimus calcium, is in Phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, according to the company investor-relations page.

Yahoo Finance lists November 13, 2026 as Immunic's next earnings date. The company has no dividend yield, while its trailing price-to-earnings ratio is negative at -1.51.

Comparison with peers

Immunic: down 3.58 percent versus the Tradegate close, price-to-earnings ratio -1.51, market capitalization USD 98.80 million.

Tyra Biosciences (Nasdaq, USD): up 1.21 percent, market capitalization USD 1.24 billion.

Spruce Biosciences (Nasdaq, USD): up 6.44 percent, market capitalization USD 130.70 million.

What comes next for Immunic

The immediate calendar marker is the November 13, 2026 earnings date, while the larger clinical milestone remains the expected Phase 3 data release by year-end 2026. The latest quarter combined a USD 0.80 per-share loss with USD 155.10 million in cash, leaving clinical progress and financing capacity central to the valuation.

Immunic was trading at EUR 6.47 at Lang & Schwarz on October 22, 2026 at 8:20 p.m. CEST, down 3.58 percent versus the Tradegate close of October 21, 2026 at EUR 6.71. The further course of trading is shown by the continuously updated real-time quote of Immunic stock.